Company Overview and News

0
Cera Sanitaryware annual report review: Resilient business, accumulate

20h moneycontrol
Cera Sanitaryware, a leader in the sanitaryware segment, reported decent volume and topline growth in a challenging FY18 as the industry witnessed multiple disruptions throughout the year. It has been a steady compounder and doubled its topline and bottomline in the past five years. The stock has seen multiple re-ratings on account of its consistent financial performance and has gained more than 5 times over the same period.
532443 CERA

0
Cera Sanitaryware Limited - Updates

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Updates

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Updates

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Tynor Orthotics raises Rs 143 crore from Lighthouse, Thuasne

2018-06-18 livemint
Mumbai: Tynor Orthotics Pvt. Ltd, a manufacturer and exporter of orthopedic and fracture aids, has raised Rs 143 crore from private equity fund Lighthouse Funds and Thuasne Participations, a French manufacturer of wearable medical devices, the company said on Monday.
532443 DHANUKA 507717 511505 CAPITALT CERA

0
Cera Sanitaryware Limited - Updates

2018-05-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Financial Results Updates

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Press Release

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Financial Result Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Dividend

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - AGM/Book Closure

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Cera Sanitaryware Limited - Outcome of Board Meeting

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532443 CERA

0
Adani Port, Vedanta, L&T Fin Holdings results

2018-05-02 thehindubusinessline
About 50 companies will declare their results on Thursday for the quarter and year ended March 2018. Among these are Adani Ports, Adani Power, Apcotex, BF Utilities, Castrol India, Century Enka, Cera Sanitaryware, Edelweiss Financial, Greaves Cotton, GTL, Hexaware, HCC, HFCL, IRB Infra, JSW Energy, L&T Finance Hold, MRF, Matrimony.com, Nucleus Software, Orient Cement, Radico Khaitan, Thirumalai Chem, Trent, Vedanta, Varun Beverages, Venky’s (India) and Umang Diaries.
ORIENTCEM 533096 CERA JSWENERGY 535754 533148 CSLQY 500280 CENTENKA 532443 532497 CASTROLIND 532430 RADICO BFUTILITIE 501455 ADANIPOWER GREAVESCOT 500870

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...